UNSPSC 51172305: Protamine sulfate

This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DE9724IHC. European Medicines Agency schedules Protamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04105MIG. Protamine sulfate generally arises in the molecular formula H2O4S. The term PROTAMINE SULFATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) Most nations schedule protamine sulfate under HS 35040000 and SITC 59225.

As of Q4 2014, PROTAMINE SULFATE remains the US FDA Preferred Term for this commodity. Protamine sulfate bears US NLM identifiers UMLS ID C0033602 and NCI Concept Code C84123. SMILES: NONE.

UNSPSC 51172305 Protamine sulfate is a Commodity code covering pharmaceutical products that state and local health, criminal justice, and employee benefits agencies source through wholesalers, direct manufacturers, or specialty testing service providers. Recent solicitations show the code used to tag drug testing services (immunoassay and confirmatory testing using LC/MS/MS or GC/MS protocols), direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical procurement under cooperative purchasing arrangements. The issuing bodies include county corrections departments, state health and human services agencies, and multistate cooperative purchasing alliances administering contracts for state departments and local government facilities. The scope spans both pharmaceutical product supply and clinical laboratory testing services for offender supervision, employee health plans, and general institutional pharmacy operations.

Geographic activity centers on Texas and Minnesota, with Texas Community Supervision and Corrections departments soliciting for drug testing services and the Texas Health and Human Services Commission conducting market research on direct-to-manufacturer prescription programs, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration procures generic pharmaceuticals and OTC products for distribution across participating state and local government facilities including Oregon. Representative current opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewal periods, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers with contract terms of two years for new responders and aligned expiration through June 30, 2028 for incumbents. The Texas Health and Human Services Commission also issued RFI HHS0017013 in late March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling future formal procurement activity in pharmacy benefit management outside traditional PBM and GPO channels.